ArticleImmunotherapy2024

A phase 1 study of the CD40 agonist MEDI5083 in combination with durvalumab in patients with advanced solid tumors.

Ben Tran et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.